<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61685">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302885</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 42914</org_study_id>
    <nct_id>NCT02302885</nct_id>
  </id_info>
  <brief_title>Healthy Human Control Blood Collection for Validation of Biomarker Assay</brief_title>
  <official_title>Human Blood Collection to Serve as Negative Control for Validation of Circulating Tumor Cell Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human blood will be collected to serve as control in validating clinical studies studying
      the detection and levels of circulating tumor cells and microvesicles in cancer patients.
      Targeted population is cancer-free 18-60 year old men and women. Volunteer selection will
      rely upon a short health questionnaire. About 20 mL blood will be collected from volunteers
      up to 20 different timepoints. The Procedure involves minimal risk of harm (eg discomfort,
      bruising) to the volunteer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>blood count</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood Collection</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      About 20 mL blood will be collected from volunteers up to 20 different timepoints.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        cancer-free 18-60 year old men and women
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range: 18-60 years old Gender: Male and Female

        Exclusion Criteria:

          -  No previously diagnosed malignancy Age: It is important to obtain a healthy,
             cancer-free volunteer population to serve as negative controls for this detection
             assay.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Simone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Simone, MD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Simone, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 11, 2016</lastchanged_date>
  <firstreceived_date>November 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer-free 18-60 year old men and women</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
